-
1 week ago | 
cancertherapyadvisor.com | Vicki Moore
A chatbot designed to educate cancer patients on genetic testing and help them access tests appears to be effective, according to research presented at the 50th Annual ONS Congress. The chatbot, named Alex, was created using formative research and patient-centered care principles. Refinement of the chatbot occurred through 2 testing phases, involving content-focused user testing and functionality-focused usability testing. Testing involved semi-structured interviews with cancer patients.
-
1 week ago | 
oncologynurseadvisor.com | Vicki Moore
The use of telehealth visits with an advanced practice provider was associated with significant improvements in patient preparedness and other positive outcomes for patients with breast cancer undergoing preparation for radiation therapy. These findings were presented at the 50th Annual ONS Congress by Sarah Ferrin, APRN-CNP, and Amber Nguyen, DNP, APRN-CNP, of the James Cancer Center at The Ohio State University Wexner Medical Center in Columbus, Ohio.
-
1 week ago | 
oncologynurseadvisor.com | Vicki Moore
Implementation of a cardio-oncology screening program appeared to be associated with timely screenings and optimal cancer treatment, according to a recent study. These study results were presented at the 50th Annual ONS Congress by a research team from St. Francis Hospital and Heart Center in Roslyn, New York, with Eileen Dwyer, BSN, RN, OCN, as the primary author.
-
3 weeks ago | 
cancertherapyadvisor.com | Vicki Moore
In a survey, 44% of cancer patients said the idea of using artificial intelligence (AI) in health care settings scares them. At the same time, 45% of patients said they can see the benefits of using AI in health care. These and other survey results were presented in a poster at the NCCN Annual Conference 2025. The researchers surveyed 666 patients who participated in the Cancer Experience Registry.
-
3 weeks ago | 
shorturl.at | Vicki Moore
Patients with lung cancer or melanoma have an increased risk of developing second primary malignancies (SPMs) after immune checkpoint inhibitor (ICI) therapy, according to research presented in a poster at the NCCN Annual Conference 2025.
-
3 weeks ago | 
oncologynurseadvisor.com | Vicki Moore
The social withdrawal subscale (SWS) from the Internalized Stigma of Mental Illness scale showed acceptable reliability and validity in measuring social withdrawal in a study of survivors of colorectal cancer (CRC) who have permanent stomas. Findings from the study were reported in the journal BMC Psychiatry. The study included 2 population samples of survivors of CRC with stomas and involved a variety of statistical analyses to assess the reliability and validity of the SWS.
-
3 weeks ago | 
oncologynurseadvisor.com | Vicki Moore
Researchers recently developed a nomogram for predicting disease-free survival (DFS) in patients with invasive triple-negative breast cancer (TNBC). They reported findings from a study evaluating its validity in the journal Clinical Breast Cancer. “The prognostic nomogram provides a potential tool to assist clinicians in risk consultation or postoperative management,” the researchers wrote in their report.
-
3 weeks ago | 
oncologynurseadvisor.com | Vicki Moore
Integrating tobacco cessation treatment into lung cancer screening (LCS) led to improved tobacco abstinence among current smokers. These findings were reported in the journal JAMA Internal Medicine. The randomized Screen Assist clinical trial (ClinicalTrials.gov Identifier: NCT03611881) included adults aged 50 to 80 years who were current smokers and were scheduled for LCS at any of 11 outpatient imaging sites during a period from April 2019 to June 2023.
-
4 weeks ago | 
oncologynurseadvisor.com | Vicki Moore
Prehabilitation interventions may improve outcomes for patients undergoing surgery for colorectal cancer (CRC), according to a new study. These study findings were reported in the Journal of the American Geriatrics Society. The study was a systematic review and meta-analysis of articles identified through searches of PubMed, Embase, CINAHL, and Cochrane Library databases from their inception until August 5, 2023.
-
1 month ago | 
shorturl.at | Vicki Moore
Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor, according to research presented at the SGO 2025 Annual Meeting on Women’s Cancer.
